Protocol 2021-LM-001 - A Multicenter Phase 1 Study to Determine the Maximum Tolerated Dose/ Maximum Feasible Dose, Safety, and Efficacy of Single Dose Rhenium-186 NanoLiposome (186RNL) Administered via Intraventricular Catheter for Leptomeningeal Metastas

Project: Research project

Project Details

StatusActive
Effective start/end date1/3/23 → 1/3/26

Funding

  • Cytori Therapeutics, Inc. ((OE) Protocol 2021-LM-001)